CTOs on the Move

Quantom Genomics

www.quantum-genomics.com

 
Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Vallon Pharmaceuticals

Vallon is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. $VLON

Family Service Association of Bucks County

Family Service offers a variety of programs and services focused on increasing opportunities for adults, protecting seniors, reducing substance abuse, improving the lives of those with mental illness, preparing children and adolescents for the future, ...

Intertek Pharmaceutical Services

Intertek Pharmaceutical Services is a Whitehouse, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovative Seating

Innovative Seating Solutions manufactures custom-fitted chairs, back orthotics and seat cushions to relieve pain and enhance seating comfort.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.